Gelonghui, February 11 | PEIJIA-B (9996.HK) saw an intraday increase of 3.25% to 4.13 Hong Kong dollars today, marking a new high for the year. PEIJIA announced last night that for the year ending December 31, 2024, the company's revenue is expected to be approximately RMB 0.61 billion to 0.63 billion, representing a year-on-year increase of about 38.3% to 42.8%. The strong revenue growth is mainly attributed to: (i) the continuous rapid growth of all the group's neurointervention product lines; and (ii) the expansion of the group's market share in the transcatheter aortic valve replacement ("TAVR") market in China. During the reporting period, significant revenue growth was achieved in the hemorrhagic, ischemic, and access neurointervention product lines due to increased surgical penetration rates, winning bids in volume-based procurement, and a comprehensive product pipeline along with effective marketing strategies. (Gelonghui)
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
-
Weekend reading | NVIDIA has made a move on Siasun Robot&Automation.
Weekend reading | In just six months of vehicle manufacturing, 32 billion was amassed, Xiaomi delivered the strongest Earnings Reports in history.
This week's Hong Kong stock bull | Yuqiang has risen over 20% this week, and its stock price has nearly doubled this year; positively rated by Institutions! Q TECH has accumulated a rise of over 18% during the week.
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
港股异动丨沛嘉医疗-B涨超3%创年内新高 去年收入同比增约38.3%-42.8%
Hong Kong stocks are moving丨PEIJIA-B rose more than 3% to set a new high for the year, with last year's revenue increasing by approximately 38.3%-42.8% year-on-year.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Views 390
Write a comment
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report